Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IDE849 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on IDE849, a putative DLL3-targeted antibody-drug conjugate (ADC) (Sep 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IDE849 | IDE-849|IDE 849 | DLL3 Antibody 10 | Limited information is currently available on IDE849, a putative DLL3-targeted antibody-drug conjugate (ADC) (Sep 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07174583 | Phase Ib/II | IDE849 | A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | Recruiting | USA | 0 |